Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.
US-based gene therapy developer Lexeo Therapeutics has emerged from stealth with an oversubscribed $85m series A round featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Lundbeck. The round was co-led by healthcare-focused venture capital firm Longitude Capital and investment firm Omega Funds and included life sciences real estate investment trust Alexandria Real Estate…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.